Vitamin B3-related NAD+ precursor fact sheet
Nicotinamide riboside
Also known as NR, niagen
Nicotinamide riboside is converted through cellular pathways toward NAD+. Human trials usually show biomarker changes, while clinical outcomes remain mixed or negative.
Quick answer
Nicotinamide riboside can raise NAD-related biomarkers in people, but it is not an FDA-approved drug for aging, cognitive decline, mitochondrial disease, or fatigue. Biomarker movement should not be confused with proven health benefit.
Published by PeptideFactSheets. Sources and methods · Research reporting, not clinical review.
What is Nicotinamide riboside?
Nicotinamide riboside is a vitamin B3-related compound and one of several precursors cells can use to make NAD+.
It is sold in dietary supplements, a category FDA does not approve for safety and effectiveness before marketing.
What do the human studies show?
Selected research questions, not a complete inventory of indications or trials. Source checking is not independent clinical review. How we read the evidence.
| Study and people | Question and follow-up | Result and limits |
|---|---|---|
| NR mild cognitive impairment pilot Older adults with mild cognitive impairment 20 participants (actual) Randomized placebo-controlled trial; human | Nicotinamide riboside versus Placebo 10 weeks Primary: Change in Montreal Cognitive Assessment score DNA methylation; secondary blood NAD+ and other functional measures. Phase: Not listed in this summary | Blood NAD+ increased; cognition did not change. Cannot tell us: Too small and short to establish prevention of dementia or rare harms. Cerebral blood-flow findings did not survive correction for multiple comparisons. Safety, uncertainty, and source detailsNo between-group difference in reported adverse events in this small pilot. Limited to the studied population, formulation and follow-up. Funding/conflicts: Not confirmed in this summary; check the full paper. Source checked: 2026-09-18. Independent clinical review: not completed. |
What these results can and cannot tell us
Did higher blood NAD+ improve cognition in the NR pilot?
Biomarker change occurred without a demonstrated cognitive improvement in this pilot.
Limit: A biomarker increase does not itself establish patient benefit or dementia prevention.
Check the sources: Nicotinamide riboside pilot in mild cognitive impairment (checked 2026-09-18)
Related, not equivalent: NAD+ · Nicotinamide mononucleotide.
Compare research questions · Submit a source-based correction
Why are people interested in it?
NR offers an oral way to influence NAD metabolism without administering NAD+ itself.
It is studied across metabolic, cardiovascular, muscle, neurological, and aging-related questions, but small trials and multiple endpoints make isolated positive signals easy to overinterpret.
Current regulatory status
No nicotinamide-riboside drug is FDA approved to prevent or treat aging, cognitive decline, mitochondrial dysfunction, or fatigue. Dietary-supplement marketing does not equal FDA approval.
What is it approved for?
No approved use is documented by the records summarized here. Commercial availability, supplement marketing, and clinical research do not equal an FDA-approved medicine.
Approval and research context
Supplement and food-ingredient status, not drug approval
Nicotinamide riboside has human biomarker trials and food-ingredient regulatory material, but no FDA-approved drug use for aging, cognition, fatigue, or disease treatment.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What is it being studied for?
Evidence snapshot
Multiple human trials establish absorption and biomarker effects. Controlled studies have not yet established a durable, reproducible benefit on cognition, physical function, or major clinical outcomes.
Potential benefits being researched
- Trials commonly report increased blood NAD-related metabolites.
- A randomized pilot in mild cognitive impairment found target engagement but did not show a significant cognitive benefit over placebo.
A mechanism, biomarker, or secondary endpoint is not proof of a meaningful clinical benefit.
Known or possible risks
- Short controlled studies generally report acceptable tolerability, but they are not large or long enough to define uncommon harms.
- Supplement strength, purity, and labeling can vary, and FDA does not preapprove supplements for effectiveness.
- Long-term consequences of chronically altering NAD metabolism in diverse populations are uncertain.
What we still do not know
- Whether any biomarker change improves healthspan or disease outcomes
- Whether a specific deficient or disease-defined population benefits
- Long-term safety and clinically meaningful interactions
- How NR compares with NMN or lifestyle interventions on patient-centered outcomes
Plain-English takeaway
NR has credible human target-engagement data, but a higher NAD biomarker is a research result—not proof of better memory, energy, or longevity.
Research and reference links
Use these primary and authoritative sources to verify status and read beyond this summary. A study or registry entry does not by itself prove benefit.
- 1pubmedRandomized NR pilot in mild cognitive impairment
Placebo-controlled pilot reporting biomarker engagement without a significant cognitive benefit.
- 2pubmedSystematic review of NAD precursor trials
Review of human NR and NMN trials describing consistent biomarker effects and heterogeneous clinical outcomes.
- 3fdaFDA GRAS notice response materials for NR chloride
Food-ingredient regulatory record; GRAS status is not approval of anti-aging or disease claims.
- 4fdaFDA: what ‘FDA approved’ does and does not mean
FDA explains that dietary supplements are not approved for safety and effectiveness before marketing.